Extended Data Fig. 5: Rate of actin-activated mantADP release from bovine cardiac myosin S1 (1 µM) in the absence and presence of 40 µM aficamten.
From: Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
Data shown are mean +/- SD (n = 16 technical replicates from n = 4 samples).
